iBio Inc
ibioinc.comiBio Inc (NYSE American: IBIO) is a clinical-stage biopharmaceutical company that discovers and develops precision antibody therapeutics using an AI/ML-assisted drug discovery platform. The company has no significant source of revenue as of the fiscal year ended June 30, 2025, operating as a pre-revenue drug discovery organization funded through equity raises including an at-the-market (ATM) program. iBio's pipeline is focused on obesity and cardiometabolic diseases, with lead candidate IBIO-600, a precision antibody that demonstrated body composition changes in non-human primate studies initiated in November 2024. The company's stated strategy combines advancing its internal pre-clinical pipeline with out-licensing its AI and antibody screening technology stack to partners in therapeutic areas such as immunology, inflammation, pain, and vaccines. Martin Brenner serves as Chief Executive Officer and Chief Scientific Officer as of the 10-K filing dated September 5, 2025.
Products & Services
IBIO-600: a precision antibody candidate targeting obesity and cardiometabolic disease, in pre-clinical development as of FY2025, with non-human primate pharmacokinetic studies initiated November 2024. AI/ML platform for antibody target discovery, hit finding, lead optimization, and epitope identification, trained on internal and third-party databases.
Revenue Model
No significant revenue as of FY2025 (fiscal year ended June 30, 2025). The company pursues a future revenue model based on drug commercialization, strategic collaborations, and out-licensing of its AI/ML platform and antibody screening technology to partners.
Customers & Markets
No commercial customers as of FY2025. Target end markets include obesity, cardiometabolic disease, immunology, inflammation, pain, and vaccines, addressed through potential future licensing and collaboration partners.
Financial Snapshot
Loading...
